Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
Figure 4
Immunohistochemical staining demonstrating the
clinical efficacy of Lapatinib. Figure 4 identifies inhibition of activated,
phosphorylated ErbB2/HER-2/neu (p-ErbB2) in a breast cancer patient responding to Lapatinib treatment. (a) Shows a
dermal-lymphatic invasion (magenta) that
is consistent with recurrent inflammatory breast cancer. (b) and (c) Show further
immunohistochemical staining for p-ErbB2 performed on tumor biopsy samples
obtained from patient X on days 0 (4B) and 21 (4C) of Lapatinib therapy; note
the change in positive staining (brownish-yellow).
There is a significant decrease in the activation of p-ErbB2 in response to
Lapatinib [37, 38].
